##plugins.themes.bootstrap3.article.main##

Pterygium is an ocular surface disease characterized by invasive fibrovascular growth due to pathological proliferation and inflammation on the conjunctival and corneal tissue. Its occurrence has been associated with chronic ultraviolet exposure, thus becoming one of the most common eye problems in tropical regions worldwide. Although pterygium rarely causes severe visual disturbances or blindness, it often becomes a distressing problem because of the high recurrence rate and unsatisfactory cosmetic outcomes, despite receiving removal management. In recent decades, studies regarding molecular mechanisms and management of pterygium have been advanced. This review provides a brief update on the mechanism and management to achieve more optimal and satisfactory pterygium therapeutic approaches.

Downloads

Download data is not yet available.

References

  1. L. Liu, J. Wu, J. Geng, Z. Yuan, D. Huang, “Geographical prevalence and risk factors for pterygium: a systematic review and metaanalysis,” BMJ Open, vol. 3, no. 11, pp. e003787, Nov 2013.
     Google Scholar
  2. R. Asokan, R. S. Venkatasubbu, L. Velumuri, V. Lingam, R. George, “Prevalence and associated factors for pterygium and pinguecula in a South Indian population,” Ophthalmic Physiol. Opt., vol. 32, no. 1, pp. 39-44, Jan 2012.
     Google Scholar
  3. F. Rezvan, M. Khabazkhoob, E. Hooshman, A. Yekta, M. Saatchi, H. Hashemi, “Prevalence and risk factors of pterygium: a systematic review and meta-analysis,” Surv. Ophthalmol., vol. 63, no. 5, pp. 719-735, Sep-Oct 2018.
     Google Scholar
  4. R. D. Johnson, V. C. Pai, R. H. Hoft, “Historical approaches to pterygium surgery, including bare sclera and adjunctive beta radiation techniques,” in Pterygium: Techniques and Technologies for Surgical Success, J. A. Hovanesian, Ed. Thorofare, NJ: Slack Incorporated, pp. 27-36.
     Google Scholar
  5. M. Caldwell, L. Hirst, M. A. Woodward, N. Nallasamy, V. Bunya. (March 2021). Pterygium. American Academy of Ophthalmology [Online]. Available: https://eyewiki.aao.org/Pterygium.
     Google Scholar
  6. E. T. Detorakis, D. A. Spandidos, “Pathogenetic mechanisms and treatment options for ophthalmic pterygium: trends and perspectives (review),” Int. J. Mol. Med., vol. 23, no. 4, pp. 439-447, Apr 2009.
     Google Scholar
  7. L. W. Hirst, “The treatment of pterygium,” Surv. Ophthalmol., vol. 48, no. 2, pp. 145-180, Mar-Apr 2003.
     Google Scholar
  8. J. P. Fisher. (July 2019). Pterygium. Medscape [Online]. Available: https://emedicine.medscape.com/article/1192527-overview.
     Google Scholar
  9. H. A. Ginger-Eke, C. E. Ogbonnaya, C. N. Ezisi, “Pterygium: recent trends and perspectives-a review of pathogenesis and current management options,” Niger. J. Ophthalmol., vol. 26, no. 2, pp. 89-98, Jan 2018.
     Google Scholar
  10. W. P. Zhou, Y. F. Zhu, B. Zhang, W. Y. Qiu, Y. F. Yao, “The role of ultraviolet radiation in the pathogenesis of pterygia (review),” Mol. Med. Rep., vol. 14, no. 1, pp. 3-15, Jul 2016.
     Google Scholar
  11. J. C. S. Yam, A. K. H. Kwok, “Ultraviolet light and ocular diseases,” Int. Ophthalmol., vol. 34, pp. 383-400, Apr 2014.
     Google Scholar
  12. M. Zhang, Z. Liu, Y. Xie, “The study on the expression of keratin proteins in pterygial epithelium,” Yan Ke Xue Bao, vol. 16, no. 1, pp. 48-52, Mar 2000.
     Google Scholar
  13. Y. Dake, R. Mukae, Y. Soda, M. Kaneko, T. Amemiya, “Immunohistochemical localization of collagen types I, II, III, and IV in pterygium tissues,” Acta Histochem., vol. 87, no. 1, pp. 71-74, 1989.
     Google Scholar
  14. N. D. Girolamo, P. McCluskey, A. Lloyd, M. T. Coroneo, D. Wakefield, “Expression of MMPs and TIMPs in human pterygia and cultured pterygium epithelial cells,” Invest. Ophthalmol. Vis. Sci., vol. 41, no. 3, pp. 671-679, Mar 2000.
     Google Scholar
  15. C. Pérez-Rico, G. Pascual, S. Sotomayor, M. Á. Montes-Mollón, C. Trejo, T. Sasaki, et al., “Tropoelastin and fibulin overexpression in the subepithelial connective tissue of human pterygium,” Am. J. Ophthalmol., vol. 151, no. 1, pp. 44-52, Jan 2011.
     Google Scholar
  16. N. D. Girolamo, R. K. Kumar, M. T. Coroneo, D. Wakefield, “UVB-mediated induction of interleukin-6 and -8 in pterygia and cultured human pterygium epithelial cells,” Invest. Ophthalmol. Vis. Sci., vol. 43, no. 11, pp. 3430-3437, Nov 2002.
     Google Scholar
  17. Z. M. Huang, Z. Q. Zhang, Y. F. Li, H. Du, X. M. Yao, “Interleukine-l alpha expression in primary and recurrent pterygium,” Chin. J. Pract. Ophthalmol., vol. 28, no. 4, pp. 407-409, 2010.
     Google Scholar
  18. B. Jabarin, A. Solomon, R. Amer, “Interleukin-17 and its correlation with vascular endothelial growth factor expression in ocular surface pathologies: a histologic study,” Eur. J. Ophthalmol., vol. 26, no. 4, pp. 283-286, Jun 2016.
     Google Scholar
  19. N. D. Girolamo, J. Chui, M. T. Coroneo, D. Wakefield D, “Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases,” Prog. Retin. Eye Res., vol. 23, no. 2, pp. 195-228, Mar 2004.
     Google Scholar
  20. E. Bianchi, F. Scarinci, C. Grande, R. Plateroti, P. Plateroti, A. M. Plateroti, et al., “Immunohistochemical profile of VEGF, TGF-β and PGE2 in human pterygium and normal conjunctiva: experimental study and review of the literature,” Int. J. Immunopathol. Pharmacol., vol. 25, no. 3, pp. 607-615, Jul-Sep 2012.
     Google Scholar
  21. J. Fukuhara, S. Kase, T. Ohashi, R. Ando, Z. Dong, K. Noda, et al., “Expression of vascular endothelial growth factor C in human pterygium,” Histochem. Cell Biol., vol. 139, no. 2, pp. 381-389, Feb 2013.
     Google Scholar
  22. M. Mood, S. K. Mittal, S. Kishore, A. Singh, N. Gupta, R. Rana, “Expression of p53 and Ki-67 proteins in patients with increasing severity and duration of pterygium,” Indian J. Ophthalmol., vol. 69, no. 4, pp. 847-850, Apr 2021.
     Google Scholar
  23. F. S. Ramalho, C. Maestri, L. N. Z. Ramalho, A. Ribeiro-Silva, E. Romão, “Expression of p63 and p16 in primary and recurrent pterygia,” Graefes. Arch. Clin. Exp. Ophthalmol., vol 244, no. 10, pp. 1310-1314, Oct 2006.
     Google Scholar
  24. S. Kase, S. Takahashi, I. Sato, K. Nakanishi, K. Yoshida, S. Ohno, “Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium,” Br. J. Ophthalmol., vol. 91, no. 7, pp. 958-961, Jul 2007.
     Google Scholar
  25. L. Tong, “Expression of p27(KIP1) and cyclin D1, and cell proliferation in human pterygium,” Br. J. Ophthalmol., vol. 92, no. 1, pp. 157, Jan 2008.
     Google Scholar
  26. K. Liang, Z. Jiang, B. Ding, P. Cheng, D. Huang, L. Tao, “Expression of cell proliferation and apoptosis biomarkers in pterygia and normal conjunctiva,” Mol. Vis., vol. 17, pp. 1687-1693, Jun 2011.
     Google Scholar
  27. E. Süren, D. Nergiz, B. Bilgin, D. T. Çoban, Z. Akgündüz, C. Sadullahoğlu, et al., “The role of cyclin D1, BCL-2, p53 and Ki-67 in epithelial cells in the etiopathogenesis of pterygium,” Indian J. Pathol. Microbiol., vol. 64, no. 2, pp. 238-242, Apr 2021.
     Google Scholar
  28. C. Maxia, M. T. Perra, P. Demurtas, L. Minerba, D. Murtas, F. Piras, et al., “Expression of survivin protein in pterygium and relationship with oxidative DNA damage,” J. Cell Mol. Med., vol. 12, no. 6A, pp. 2372-2380, Dec 2008.
     Google Scholar
  29. Y. Xu, L. Zhang, D. Zou, Z. Liu, X. Shang, H. Wu, et al., “Differential expression and function of survivin during the progress of pterygium,” Invest. Ophthalmol. Vis. Sci., vol. 55, no. 12, pp. 8480-8487, Dec 2014.
     Google Scholar
  30. Y. Liu, H. Xu, M. An, “mTORC1 regulates apoptosis and cell proliferation in pterygium via targeting autophagy and FGFR3,” Sci. Rep., vol. 7, no. 7339, Aug 2017.
     Google Scholar
  31. Y. H. Cui, H. Y, Li, Z. X. Gao, N. Liang, S. S. Ma, F. J. Meng, et al., “Regulation of apoptosis by miR-122 in pterygium via targeting Bcl-w,” Invest. Ophthalmol. Vis. Sci., vol. 57, no. 8, pp. 3723-3730, Jul 2016.
     Google Scholar
  32. D. Pagoulatos, N. Pharmakakis, J. Lakoumentas, M. Assimakopoulou, “Ηypoxia-inducible factor-1α, von Hippel-Lindau protein, and heat shock protein expression in ophthalmic pterygium and normal conjunctiva,” Mol. Vis., vol. 20, pp. 441-457, Mar 2014.
     Google Scholar
  33. A. S. Dogan, E. Onder, A. T. Arikok, T. Bicer, C. Gurdal, “Claudin-1 expressions decrease in pterygium with respect to normal conjunctiva,” Cutan. Ocul. Toxicol., vol. 35, no. 4, pp. 315-318, Dec 2016.
     Google Scholar
  34. U. Beden, M. Irkec, D. Orphan, M. Orphan, “The roles of T-lymphocyte subpopulations (CD4 and CD8), intercellular adhesion molecule-1 (ICAM-1), HLA-DR receptor, and mast cells in etiopathogenesis of pterygium,” Ocul. Immunol. Inflamm., vol. 11, no. 2, pp. 115-122, Jun 2003.
     Google Scholar
  35. S. Kase, M. Osaki, I. Sato, S. Takanashi, K. Nakanishi, K. Yoshida, et al., “Immunolocalisation of E-cadherin and beta-catenin in human pterygium,” Br. J. Ophthalmol., vol. 91, no. 9, pp. 1209-1212, Sep 2007.
     Google Scholar
  36. A. Alpay, S. H. Uğurbaş, B. Erdoğan, “Comparing techniques for pterygium surgery,” Clin. Ophthalmol., vol. 3, pp. 69-74, 2009.
     Google Scholar
  37. S. I. Van Acker, M. Haagdorens, E. Roelant, J. Rozema, T. Possemiers, V. Van Gerwen, “Pterygium pathology: a prospective case-control study on tear film cytokine levels, vol. 2019, no. 9416262, Nov 2019.
     Google Scholar
  38. D. Hacıoğlu, H. Erdöl, “Developments and current approaches in the treatment of pterygium,” Int. Ophthalmol., vol. 37, no. 4, pp. 1073-1081, Aug 2017.
     Google Scholar
  39. J. Parker. (Januart 2021). Surgical approaches to pterygium. Review of Ophthalmology [Online]. Available: https://www.reviewofophthalmology.com/article/surgical-approaches-to-pterygium.
     Google Scholar
  40. F. Pereira, H. F. Shiroma, M. G. Urias, V. H. Yamada, A. A. S. Lima, A. L. Hofling-Lima, et al., “Pilot study comparing topical anesthetic agents in pterygium surgery: subconjunctival injection versus 2% lidocaine gel versus 5% lidocaine gel,” Cornea, vol. 37, no. 2, pp. 194-198, Feb 2018.
     Google Scholar
  41. H. Oksuz, C. Tamer, “Efficacy of lidocaine 2% gel in pterygium surgery,” Acta Ophthalmol. Scand., vol. 83, pp. 206-209, 2005.
     Google Scholar
  42. V. Damle, “A study to compare conjunctival autografting with sutures and glue free sutureless technique after primary pterygium excision,” Int. J. Sci. Study, vol. 5, no. 9, pp. 142-147, 2017.
     Google Scholar
  43. S. K. Singh, “Pterygium: epidemiology prevention and treatment,” Community Eye Health, vol. 30, no. 99, pp. S5-S6, Jan 2017.
     Google Scholar
  44. K. C. Apaydin, Y. Duranoglu, O. Saka, N. Demirbas, “Argon laser treatment of pterygium,” Ann. Ophthalmol., vol. 34, pp. 26-29, Mar 2002.
     Google Scholar
  45. D. Chen, X. Liu, Q. Long, Z. Wang, Y. Li, “Effects of excimer laser phototherapeutic keratectomy in limbal-conjunctival autograft transplantation for recurrent pterygium: a retrospective case control study,” BMC Ophthalmol., vol. 19, no. 238, Nov 2019.
     Google Scholar
  46. K. H. Chen, W. M. Hsu, “Intraoperative ethanol treatment as an adjuvant therapy of pterygium excision,” Int. J. Biomed. Sci., vol. 2, no. 4, pp. 414-421, Dec 2006.
     Google Scholar
  47. D. Todorovic, T. Sarenac-Voluvic, S. Sreckovic, S. Jovanovic, K. Janicijevic, Z. Todorovic, “Updates on the treatment of pterygium,” Serbian J. Exp. Clin. Res., vol. 17, no. 3, pp. 257-261, Sept 2016.
     Google Scholar
  48. A. L. Young, P. M. Tam, G. Y. Leung, L. L. Cheng, P. T. Lam, D. S. Lam, et al., “Prospective study on the safety and efficacy of combined conjunctival rotational autograft with intraoperative 0.02% mitomycin C in primary pterygium excision,” Cornea, vol. 28, no. 2, pp. 168-169, Feb 2009.
     Google Scholar
  49. J. Frucht-Pery, F. Raiskup, M. Ilsar, D. Landau, F. Orucov, A. Solomon, “Conjunctival autografting combined with low dose mitomycin C for prevention of primary pterygium recurrence,” Am. J. Ophthalmol., vol. 141, no. 6, pp. 1044-1050, Jun 2006.
     Google Scholar
  50. G. Koranyi, D. Artzen, S. Seregard, E. D. Kopp, “Intraoperative mitomycin C versus autologous conjunctival autograft in surgery of primary pterygium with four-year follow up,” Acta Ophthalmol., vol. 90, no. 3, pp. 266-270, May 2012.
     Google Scholar
  51. M. C. Biswas, C. Shaw, R. Mandal, “Treatment of pterygium with conjunctival limbal autograft and mitomycin C - a comparative study,” J. Indian Med. Assoc., vol. 105, no. 4, pp. 202-204, Apr 2007.
     Google Scholar
  52. C. C. Teng, N. N. Patel, L. Jacobson, “Effect of subconjunctival bevacizumab on primary pterygium,” Cornea, vol. 28, no. 4, pp. 468-470, May 2009.
     Google Scholar
  53. A. Shenasi, F. Mousave, S. Shoa-Ahari, B. Rahimi-Ardabili, R. F. Fouladi, “Subconunctival bevacizumab immediately after excision of primary pterygium: the first clinical trial,” Cornea, vol. 30, no. 11, pp. 1219-1222, Nov 2011.
     Google Scholar
  54. L. R. Stival, A. M. Lago, M. N. Figueiredo, R. H. Bittar, M. L. Machado, J. J. Nassaralla Junior, “Efficacy safety of subconjunctival bevacizumab for recurrent pterygium,” Arg. Bras. Oftalmol., vol. 77, no. 1, pp. 4-7, Jun 2013.
     Google Scholar
  55. C. Akarsu, P. Taner, A. Ergin, “5-Fluorouracil as chemoadjuvant for primary pterygium surgery: preliminary report,” Cornea, vol. 22, no. 6, pp. 522-526, Aug 2003.
     Google Scholar
  56. P. Prabhasawat, N. Tesavibul, K. Leelapatranura, T. Phonjan, “Efficacy of subconjunctival 5-fluorouracil and triamcinolone injection in impending recurrent pterygium,” Ophthalmology, vol. 113, no. 7, pp. 1102-1109, Jul 2006.
     Google Scholar
  57. K. Kampitak, W. Leelewongtawun, S. Leeamornsiri, W. Suphachearaphan, “Role of artificial tears in reducing the recurrence of pterygium after surgery: a prospective randomized controlled trial,” Acta Ophthalmol., vol. 95, no. 3, pp. e227-e229, May 2017.
     Google Scholar